Fig. 5From: Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapyBayesian ranking profile based on the SUCRA results of progression-free survival, overall survival, objective response rate, and decrement rate of grade 3–4 assessmentBack to article page